The Electronic Directory for People with Spinal Cord Injury
"Because no one should cope with a Spinal Cord Injury (SCI) alone"
|
The Electronic Directory for People with Spinal Cord Injury "Because no one should cope with a Spinal Cord Injury (SCI) alone" |
|
|
World Renowned Spinal Cord Specialist, Dr. Martin Grumet, from Rutgers University, to Visit BrainStorm Cell Therapeutics' Headquarters to Discuss Experiment Results
NEW YORK &
PETACH TIKVAH, Israel — BrainStorm Cell
Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell
technologies and therapeutics, is pleased to announce that the world renowned
Spinal Cord specialist Dr. Martin Grumet, Director of the W.M. Keck Center for
Collaborative Neuroscience, at Rutgers University, will visit company
headquarters next week in Petach Tikva, Israel.
BrainStorm announced in January that the Company had expanded its collaboration with Rutgers University in an effort to cure spinal cord injuries through BrainStorm's cutting-edge adult stem cell research. Dr. Grumet's visit will be dedicated to analyzing the various results, and discussing the effects of transplanting BrainStorm NTF cells into spinal cord injured mice models. After final results and histology are analyzed the company together with Rutgers expects to publish the results. "We are happy to welcome yet again Dr. Grumet and, with God's help, anticipate to learn and gain from the in depth data for the future development of Brainstorm's NTF Stem Cell technology", commented Chaim Lebovits, BrainStorm's President. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's, ALS and Spinal Cord Injury, although its technology has promise for treating several others diseases including MS, Huntington's disease and stroke. About Rutgers University Established in 1766, Rutgers, The State University of New Jersey, is America's eighth oldest institution of higher learning and one of the nation's premier public research universities. Serving more than 50,000 students on campuses in Camden, Newark and New Brunswick, Rutgers offers more than 280 bachelor's, master's, doctoral and professional degree programs. The university is home to 27 degree-granting schools and colleges, and more than 150 specialized centers and institutes. Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete its equity financing transactions previously disclosed. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; dependence on its license to Ramot's technology; ability, together with its licensor, to adequately protect the NurOwn(tm) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us. BrainStorm Cell Therapeutics Inc. Chaim Levinson, +972-545-633683 Clevinson@brainstorm-cell.com
|
|
|
